Datavault AI Grants Scilex Exclusive License for Biotech Exchange Platform in $2.55 Billion Deal
Datavault AI has licensed its AI-driven technology to Scilex for a biotech exchange platform that could address a $2 trillion pharmaceutical market, representing a major advancement in tokenizing and monetizing healthcare assets.
Datavault AI has granted Scilex Holding Company an exclusive worldwide license to deploy its proprietary AI-driven technology within the biotech and biopharma sectors. The agreement enables Scilex to build and operate a Biotech Exchange platform to tokenize, trade, and monetize biotech assets such as genomic data, diagnostics, and drug information. This licensing arrangement represents a significant step toward creating new financial infrastructure for the healthcare industry.
The deal includes a $10 million upfront payment in four installments and up to $2.55 billion in potential milestone payments, supported by Datavault AI's broad patent portfolio and proven high-performance computing expertise. The substantial financial commitment underscores the potential market value of tokenizing biotech assets and creating new revenue streams for pharmaceutical companies and research institutions. The technology is expected to expand into a Pharmaceutical Exchange platform addressing an estimated $2 trillion market opportunity.
This development matters because it provides a path for biotech and pharmaceutical companies to access non-dilutive funding through asset tokenization. By creating a marketplace for trading tokenized biotech assets, the platform could revolutionize how research data and intellectual property are valued and monetized. The ability to securely trade genomic data, diagnostics, and drug information could accelerate research and development while creating new revenue models for healthcare organizations.
The implications extend beyond immediate financial benefits, potentially transforming how biotech assets are managed and commercialized. The platform's foundation in Datavault AI's technology, including its Information Data Exchange that enables Digital Twins and licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata objects, positions it as a comprehensive solution for asset management in the Web 3.0 environment. This approach could set new standards for data security and transparency in biotech transactions.
For more information about Datavault AI's technology platform, visit https://www.datavaultsite.com. The full press release detailing this agreement can be accessed at https://ibn.fm/HAV6r, while comprehensive terms of use and disclaimers are available at http://IBN.fm/Disclaimer.